EU CHMP adopts change to indication for Revolade (eltrombopag) in thrombocytopenic purpura- Novartis

The CHMP adopted a change to an existing indication as follows: Revolade (eltrombopag), from Novartis, is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year and above who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). This follows a similar update by the FDA in December 2015.